New diabetes medication reduced heart event risk in those with diabetes and kidney disease

(American Heart Association) Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.Researchers say the results of this randomized clinical trial provide evidence that SGLT2 inhibitors should be part of the standard of care for people with Type 2 diabetes and chronic kidney disease.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news